低剂量率近距离放疗后非前列腺癌死亡预测年轻患者长期生存
研究纳入782例≤59岁接受低剂量率近距离放疗(±补充治疗)的前列腺癌患者,中位随访12.1年。15年生化失败率、前列腺癌特异性死亡率、总死亡率分别为4.9%、1.8%、16.5%;总生存改善需针对可改变健康风险进行积极管理。
要点
- ≤59岁患者近距离放疗后15年生化失败率仅4.9%,肿瘤学结局良好。
- 总死亡率独立预测因素包括年龄、糖尿病和当前吸烟。
核心结论
- 年轻前列腺癌患者接受近距离放疗后肿瘤学结局良好,但非前列腺癌死亡显著多于前列腺癌死亡,改善总生存需多措并举改变生活方式并积极管理可改变健康风险。
研究设计与样本
- 单中心回顾性队列研究,纳入782例连续≤59岁接受低剂量率近距离放疗(±补充治疗)的前列腺癌患者,按年龄分为≤54岁(n=331)和55–59岁(n=451)两队列。
主要发现
- 全队列15年生化失败率、前列腺癌特异性死亡率和总死亡率分别为4.9%、1.8%和16.5%。
- ≤54岁与55–59岁组15年生化失败率分别为6.1%和4.0%(p=.205),总死亡率分别为11.6%和20.1%(p=.002)。
- 前列腺癌死亡占全部死亡的12.3%,心血管疾病和其他恶性肿瘤占61.4%。
- 多变量分析中,总死亡率预测因素为年龄(HR 1.105;p=.002)、糖尿病(HR 1.890;p=.036)和当前吸烟(HR 2.989;p<.001)。
临床怎么用
- 对年轻前列腺癌近距离放疗后患者,应强化心血管疾病和其他恶性肿瘤的筛查与防控。
- 积极管理糖尿病、戒烟等可改变健康风险,可能改善长期总生存。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite favorable biochemical and functional outcomes in younger patients treated with prostate brachytherapy, overall survival remains compromised by a plethora of nonprostate cancer deaths, especially those attributable to sedentary lifestyle or modifiable health risks. In this study, we evaluate cancer control and patterns of death and propose recommendations for lifestyle changes and aggressive management of medical comorbidities. METHODS AND MATERIALS: A total of 782 consecutive men aged ≤59 years underwent brachytherapy with or without supplemental therapies. Patients were stratified into 2 age cohorts: ≤54 years (n = 331) and 55 to 59 years (n = 451). Postimplant dosimetry was based on the day 0 computed tomography evaluation. Biochemical failure (BF) was defined as prostate-specific-antigen (PSA) > 0.40 ng/mL after nadir. Patients with metastatic prostate cancer or nonmetastatic castrate-resistant disease who died of any cause were classified as deaths from prostate cancer. All other deaths were attributed to the immediate cause of death. Multiple clinical, pathologic, and treatment parameters were evaluated for their impact on survival. RESULTS: No significant differences in presentation were observed between the 2 cohorts, except that hypertension and tobacco use were statistically more common in the 55- to 59-year-old age group. The median follow-up was 12.1 years. A total of 40.8% of patients presented with unfavorable intermediate- or high-risk disease. The median day 0 minimum dose of radiation to 90% of the prostate gland (D90) was 122.1%. For the entire cohort, the 15-year BF, prostate cancer-specific mortality, and overall mortality (OM) rates were 4.9%, 1.8%, and 16.5%, respectively. When stratified by age, the 15-year BF rates were 6.1% and 4.0% in the younger and older cohorts, respectively (p = .205). The 15-year OM rates were 11.6% and 20.1% in the ≤54- and 55- to 59-year-old groups, respectively (p = .002). Prostate cancer accounted for 12.3% of all deaths, with cardiovascular disease and other malignancies comprising 61.4%. In multivariate analysis (MVA), BF was best predicted by high risk (subdistribution hazard ratio [sHR], 10.180; p ≤ .001) and percent positive biopsies (sHR, 1.024; p = .004), prostate cancer-specific mortality by percent positive biopsies (sHR, 1.030; p = .024), and OM by age (hazard ratio [HR], 1.105; p = .002), diabetes (HR, 1.890; p = .036), and current tobacco use (HR, 2.989; p < .001). CONCLUSIONS: Brachytherapy generates favorable oncologic outcomes in younger men with prostate cancer. Nonprostate cancer deaths substantially outnumber prostate cancer deaths, with the majority due to cardiovascular disease or other malignancies. Improvement in overall survival will require multiple lifestyle changes and aggressive management of modifiable health risks.
引用
- Orio P, Mirić G, Galbreath R, et al. Nonprostate Cancer Deaths Best Predict Long-Term Survival in Men Aged ≤59 Years Treated With Low Dose Rate Brachytherapy With or Without Supplemental Therapies: A Mandate for Health Enhancement. Adv Radiat Oncol. 2026. PMID: 42438566. doi:10.1016/j.adro.2026.102101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。